VRTX Q1 2023 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.4B+13.2% YoY

Gross Profit

$2.1B88.8% margin

Operating Income

$779M32.8% margin

Net Income

$700M29.5% margin

EPS (Diluted)

$2.69

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$900M

Free Cash Flow

$858M

Stock-Based Comp.

$122M

Balance Sheet

Total Assets

$19.0B

Total Liabilities

$4.5B

Stockholders' Equity

$14.4B

Cash & Equivalents

$9.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.1B	+13.2%
Gross Profit	$2.1B	$1.9B	+13.8%
Operating Income	$779M	$1.0B	-25.2%
Net Income	$700M	$762M	-8.2%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.1B88%

KALYDECO

$125M5%

ORKAMBI

$123M5%

SYMDEKO/SYMKEVI

$31M1%

Geographic Segments

UNITED STATES

$1.4B59%

Europe

$807M34%

Other, Non U.S.

$164M7%